Compare EVAX & GRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVAX | GRF |
|---|---|---|
| Founded | 2008 | 1989 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.7M | 42.6M |
| IPO Year | 2021 | N/A |
| Metric | EVAX | GRF |
|---|---|---|
| Price | $5.85 | $11.58 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $12.33 | N/A |
| AVG Volume (30 Days) | ★ 98.3K | 3.0K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.70% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.16 |
| Revenue | ★ $7,650,000.00 | N/A |
| Revenue This Year | $128.77 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.15 |
| Revenue Growth | ★ 132.17 | N/A |
| 52 Week Low | $1.20 | $7.93 |
| 52 Week High | $12.15 | $10.19 |
| Indicator | EVAX | GRF |
|---|---|---|
| Relative Strength Index (RSI) | 52.12 | 54.50 |
| Support Level | $5.72 | $11.16 |
| Resistance Level | $6.70 | $11.85 |
| Average True Range (ATR) | 0.47 | 0.32 |
| MACD | 0.03 | 0.11 |
| Stochastic Oscillator | 50.26 | 58.62 |
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock by giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.